Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYD12: Dengue Vaccine Formulations in Healthy Adults
NCT00617344Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2008
- Primary completion
- Dec 2009
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever, sponsored by Sanofi. Started Apr 2008; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT00617344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617344.